Can Zofran (ondansetron) be used to treat opioid-induced pruritus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ondansetron (Zofran) for Opioid-Induced Pruritus

Ondansetron is not recommended as a first-line treatment for opioid-induced pruritus as it does not reduce the incidence of pruritus compared to placebo, though it may reduce severity in some cases. 1

Efficacy of Ondansetron for Opioid-Induced Pruritus

  • Opioid-induced pruritus is common, affecting 2-10% of patients receiving oral opioids, 10-50% receiving intravenous opioids, and 20-100% receiving epidural or intrathecal opioids 1
  • According to the British Association of Dermatologists' guidelines, ondansetron and other 5-HT3 receptor antagonists do not reduce the incidence of opioid-induced pruritus or time to onset when compared with placebo 1
  • While some evidence suggests ondansetron 4 mg or 8 mg may reduce the severity or need for treatment of pruritus secondary to opiates, this has been refuted in more recent studies 1

Recommended Treatment Algorithm for Opioid-Induced Pruritus

First-line options:

  • Antihistamines such as diphenhydramine or promethazine are recommended as initial treatment 1
  • Assess for other causes of pruritus, as pruritus is more likely to occur early in the course of opioid treatment 1

Second-line options (if antihistamines fail):

  • Opioid antagonists have proven useful when antihistamines fail 1
  • Mixed agonist/antagonists (e.g., nalbuphine) can be used to treat opioid-induced pruritus 1, 2
  • μ-opioid receptor antagonists (e.g., naloxone, naltrexone) can be used with careful dose titration to produce relief without reversing analgesic efficacy 1, 3
  • Methylnaltrexone (a peripheral opioid antagonist with reduced ability to cross the blood-brain barrier) can be considered 1, 3

Third-line options:

  • Consider opioid rotation if pruritus persists despite symptomatic management 1
  • Diclofenac 100 mg rectally has shown efficacy in reducing postoperative pruritus 1, 3
  • Mirtazapine 30 mg daily orally or gabapentin 1200 mg daily in divided doses have shown efficacy in preventing morphine-induced pruritus in surgical settings 1, 3

Important Clinical Considerations

  • The use of opioid antagonists in treating opioid-induced pruritus risks inducing significant pain by reversing analgesia, requiring careful dose titration 1
  • Pruritus is particularly common with neuraxial (epidural and intrathecal) opioid administration 4
  • While some small studies have reported success with ondansetron for opioid-induced pruritus 5, 6, the highest quality evidence from guidelines does not support its routine use 1
  • Intranasal butorphanol has shown promise in small studies for treating opioid-induced pruritus unresponsive to antihistamines 2

Common Pitfalls to Avoid

  • Do not rely on ondansetron as a first-line treatment for opioid-induced pruritus despite its efficacy for opioid-induced nausea 1
  • Avoid using full doses of opioid antagonists in opioid-dependent patients as this may precipitate withdrawal 1
  • Don't overlook other causes of pruritus in patients receiving opioids, such as other medications or underlying skin conditions 1
  • Remember that pruritus can be so severe that it may require modification or abandonment of opioid therapy if unresponsive to treatment 2, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Generalized Pruritus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Neuraxial opioid-induced pruritus: An update.

Journal of anaesthesiology, clinical pharmacology, 2013

Research

Opioid-induced pruritus: an update.

Clinical and experimental dermatology, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.